HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Boiron Partners With Galenica's Verfora In Switzerland

Executive Summary

France's Boiron has granted Galenica's Verfora the rights to distribute in Switzerland its portfolio of over 800 products as it looks to turnaround its business and make cost savings following the collapse of homeopathy sales in its home market.

You may also be interested in...



Boiron Moves Into Personalized Beauty As Sales Continue To Slide

France's Boiron has acquired cosmetics player ABBI, which uses artificial intelligence to offer consumers personalized beauty products. The move comes as Boiron reported 2021 sales down double-digits as homeopathy sales in its home market continue to decline.

Acquisitions Help Drive Up Sales At Switzerland's Galenica In 2021

Galenica's Swiss consumer health business Verfora saw sales jump by a fifth in 2021 thanks to key acquisitions. Without the impact of these deals, Verfora's sales over the 12 months would have declined due to the negative impact of the pandemic on its business.

EU Business Round-Up: Galenica Acquires Spagyros, Karo Offloads OTCs, And Ceres Gets New Owners

The latest European business news: Galenica strengthens its porfolio in Switzerland with Spagyros; Sweden's Karo offloads OTCs to Evolan; and Ceres Pharma sold to French private-equity firm.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152696

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel